Ittrio (90y) Citrato Curium Italy (Yttrium (90y) Citrate)

Yttrium-90 citrate emits beta radiation that penetrates the synovial membrane. The radiation destroys proliferating inflammatory synovial cells while sparing surrounding tissues, resulting in a chemical synovectomy that decreases joint inflammation and improves function without the need for surgical removal.

The dose of Ittrio is individualized by the prescribing physician based on joint size, disease severity and patient factors. The prescriber determines the appropriate activity (in megabecquerels) and volume to be injected for each specific joint.

Safety of Ittrio in pregnancy or lactation has not been established. Because it involves localized radiation, it is generally avoided in pregnant or nursing patients unless the potential therapeutic benefit clearly outweighs the possible risk to the fetus or infant.

To order Ittrio, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Ittrio uses Yttrium-90, a high‑energy beta emitter, offering deeper tissue penetration compared with agents like Phosphorus‑32. This can be advantageous for larger joints but may require careful dosing. Clinical choice depends on joint size, disease characteristics and physician experience.

Ittrio must be stored refrigerated at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial, and handle it according to local radiation safety regulations to prevent contamination and maintain product stability.

Ittrio is administered as an intra‑articular injection by a qualified healthcare professional. After aseptic preparation of the joint, the calculated volume of the Yttrium-90 citrate solution is injected directly into the synovial cavity under imaging guidance if needed.

Serious risks include radiation‑induced cartilage damage, severe joint infection (septic arthritis), systemic radiation exposure leading to hematologic effects, and, very rarely, secondary malignancy in the treated joint. Patients should be monitored closely for signs of infection or unexpected joint deterioration.

Ittrio is contraindicated in patients with active joint infection, severe osteoarthritis where synovectomy is not indicated, pregnant or nursing women (unless benefits outweigh risks), and individuals with uncontrolled bleeding disorders without appropriate correction.